Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportRadiopharmaceutical Chemistry: New Radiopharmaceuticals

Analysis of tumor uptake of Iod-123-Methyltyrosine in fused PET-MRI in a mouse xenotransplantation model of pancreatic cancer

Corinna Forstner, Maaz Zuhayra, Laszlo Papp and Eberhardt Henze
Journal of Nuclear Medicine May 2009, 50 (supplement 2) 1930;
Corinna Forstner
1University Hospital of Schleswig-Holstein, Campus Kiel, Germany, Department of Nuclear Medicine, Kiel, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maaz Zuhayra
1University Hospital of Schleswig-Holstein, Campus Kiel, Germany, Department of Nuclear Medicine, Kiel, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laszlo Papp
1University Hospital of Schleswig-Holstein, Campus Kiel, Germany, Department of Nuclear Medicine, Kiel, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eberhardt Henze
1University Hospital of Schleswig-Holstein, Campus Kiel, Germany, Department of Nuclear Medicine, Kiel, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1930

Objectives In pancreatic cancer imaging with F-18-FDG-PET has shown to be usefull, however its not available just anywhere. Therefore substitution with a more commonly used tracer like Iod-123-Methyltyrosine (I-123-IMT) would be helpful for imaging of pancreatic cancer .The aim of the underlying study was to examine its uptake in an animal modell.

Methods A celline of pancreatic cancer (PancTull) was transplanted orthotopically and subcutaneously respectively in eight SCID-beige-mice which received 15 MBq of I-123-IMT for imaging. Two hours after injection combined imaging was performed with micro-SPECT and a 3T MR scanner using a dedicated mouse coil. Tumor uptake analysis was based on ROI interpretation using a Tumor/Background ratio (T/B) with the adjacent visceral region as background.

Results In all of the eight mice a significantly higher uptake into tumor tissue could be elicited. After subcutaneous xenotransplantation the T/B was 10,25 (2,9-17,9) and after orthotopic xenotransplantation it was 11,15 (2,5-27,3). Fusion with MRI enabled good correlation of the anatomical site of the tumor with I-123-IMT uptake.

Conclusions From experiments with glioma cells it is well known that the uptake of IMT depends on an acid-anionic-transporter (LAT1) and that I-123-IMT is not incorporated into the proteins. Therefore we conclude that this specific transporter, LAT 1 is present in the underlying model of pancreatic cancer leading to the significantly higher tumor uptake. In this case the use of I-123-IMT could be considered as an economical alternative to FDG-PET in pancreatic carcinoma.

  • © 2009 by Society of Nuclear Medicine
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 50, Issue supplement 2
May 2009
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Analysis of tumor uptake of Iod-123-Methyltyrosine in fused PET-MRI in a mouse xenotransplantation model of pancreatic cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Analysis of tumor uptake of Iod-123-Methyltyrosine in fused PET-MRI in a mouse xenotransplantation model of pancreatic cancer
Corinna Forstner, Maaz Zuhayra, Laszlo Papp, Eberhardt Henze
Journal of Nuclear Medicine May 2009, 50 (supplement 2) 1930;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Analysis of tumor uptake of Iod-123-Methyltyrosine in fused PET-MRI in a mouse xenotransplantation model of pancreatic cancer
Corinna Forstner, Maaz Zuhayra, Laszlo Papp, Eberhardt Henze
Journal of Nuclear Medicine May 2009, 50 (supplement 2) 1930;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Radiopharmaceutical Chemistry: New Radiopharmaceuticals

  • Evaluation of [64Cu]DOTA-annexin V radiotracer in the cycloheximide-induced liver apoptosis model
  • PET imaging of α-galactosidase A pharmacokinetics in rats and monkeys
Show more Radiopharmaceutical Chemistry: New Radiopharmaceuticals

New Radiopharmaceuticals-Oncology Posters

  • Preparation and evaluation of a tumor-associated antigen mucin (MUC1) and tumor-associated monoclonal antibody-derived hybrid peptide as a breast cancer imaging agent
  • Characterization of the two enantiomers of anti-18F-FACPC as PET tumor agents
  • In vivo evaluation of EGCG stabilized gold-198 nanoparticles in prostate cancer bearing mice
Show more New Radiopharmaceuticals-Oncology Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire